These findings, which are in agreement with the hypothesis that RGD-binding integrins are co-receptors for angiotensin-converting enzyme 2 (ACE2), used by SARS-CoV-2 to entry into the host cells [88], open the door to the possible future use of integrin inhibitors in viral infections [89]. Here, ACE2 is linked to viral infectious disease.